To analyse the comparative binding interaction with HCV targets for anti-COVID19 receptors, three targets of HCV NS3 Helicase, NS5B RNA-dependent RNA polymerase and NS3/4A S168A protease docked against 26 potential drugs along with known inhibitors. The result indicated, Chloroquine antiplasmodial drug computationally significant for three HCV receptors but the same is less significant for COVID19 (Figure ). Similarly, anti-HIV drugs Dolutegravir and Maraviroc had considerable binding against HCV targets but less potential with COVID19 receptors. Conversely, Elbasvir, Ledipasvir reacted with related potential against Helicase, RdRp and Protease from both virus HCV and COVID19. This projected the potential of anti-HCV drugs for inhibition of the COVID19 virus.